The cannabis industry does not have a capital problem in the way many operators like to describe it. Capital still exists. Debt remains available to qualified operators, lenders continue to evaluate deals, and investors have not abandoned the space. But capital providers have changed their expectations, while too many operators are still trying to raise against an old story.
The old story was familiar: Secure the license, build the facility, expand the footprint, wait for legalization, and position for the inevitable strategic exit. For years, that story was enough to keep capital moving.
Not anymore. After a decade of missed federal timelines, compressed margins, burned investor capital, and business models that failed to scale, cannabis capital has become less interested in possibility and more interested in proof.
Patrick Rea, managing director at Poseidon Garden Ventures, said serious investors have learned not to build their decisions around potential.
“They can’t underwrite exits driven by legal or regulatory change events they can’t control,” Rea said. “They have to underwrite or make their decisions based upon the status quo.”
Those two sentences capture the shift. With debt maturities looming and refinancing pressure building across the industry, that shift is becoming harder to ignore.
The industry used to sell investors on what cannabis might become. Today, capital wants to know whether the business works under the conditions that exist right now.
- Investors increasingly evaluate cannabis companies under current market and regulatory conditions rather than banking on federal reform or an eventual strategic exit.
- Revenue alone does not make a business creditworthy; lenders want evidence of positive cash flow and a reliable path to repayment.
- Clean financials, disciplined budgeting, and rolling cash-flow forecasts can distinguish proactive operators from companies perpetually managing crises.
- Follow-on funding may reflect an investor’s existing exposure as much as confidence in the company’s standalone prospects.
The market has memory now
Seth Yakatan has spent decades raising capital and selling companies across cannabis, biotech, pharmaceuticals, and consumer goods. His read is simple: The cannabis market is no longer naive.
In the early years, he said, “if you showed up with an idea and a license, somebody would give you money.”
That era is gone. Investors now have what Yakatan calls “mistake data”: years of failed models, incinerated capital, overbuilt facilities, unrealistic valuations, and operators who could not execute at scale.
“Most serious investors don’t want to make the same kind of mistake four times,” he said.
That is a brutal adjustment for founders who believe their license, brand, market, or personal charisma should be enough. Investors have seen the comps. They know the valuation range. They know which models have already failed in other states with equally confident founders attached.
Founders may think they’re pitching a fresh opportunity, but investors may see the fourth version of a movie that already ended badly.
Debt is available. Creditworthiness is not guaranteed.
The dividing line is no longer merely cannabis versus non-cannabis. Within the industry, capital providers increasingly distinguish among pre-revenue companies, businesses with sales but weak cash flow, and operators that can demonstrate genuine creditworthiness.
Raymond Guns, chief revenue officer at DOPE CFO, said operators often misunderstand this distinction.
“If you’re a creditworthy, lendworthy company, it’s pretty straightforward to raise capital, especially debt,” Guns said. “If you’re a pre-revenue startup with no proven track record, it’s gonna be harder than it was in 2018 [or] 2020 for sure.”
But even post-revenue companies are not automatically fundable.
Generating revenue and generating positive cash flow are two very different things. A company can sell $500,000 a month and still lose money if it costs $550,000 to operate. That may look like traction to a founder. To a lender, it looks like repayment risk.
Guns put it plainly: “I don’t want to lend to a dying company.”
That is where the new capital environment becomes unforgiving. A founder can still argue that a new loan will unlock equipment, expansion, efficiency, or growth. But that is a harder story to sell than a company that is already profitable and can show how capital will make it more profitable.
In other words: Capital infusions are no longer a substitute for discipline.
The management gap
The industry has spent years blaming regulation, taxes, banking restrictions, price compression, and capital constraints for its struggles. All of those pressures are real. None of them excuse poor management.
Guns was blunt on this point. Every industry has taxes, regulations, margin pressure, and operational complexity. The question is whether leadership manages the variables it can control: labor, materials, overhead, rent, utilities, debt service, inventory, cash flow.
Well-managed businesses know their costs. Struggling operators often discover them too late.
“Cannabis [companies] got into a bad habit of never following their budgets, because nobody really was an adult in the room and they had a lot of investors’ capital,” Guns said.
That line should sting. It also should clarify the moment: The next phase of cannabis will be defined by people who can prove they know how to manage capital.
Guns described the difference as reactive versus proactive culture. Reactive companies live week to week, deciding which bill gets paid next and whether payroll clears on Friday. Proactive companies know their cash position weeks ahead, forecast expenses, manage inventory needs before they become emergencies, and keep finance and operations in constant conversation.
The tools do not have to be exotic. Guns pointed to a thirteen-week cash-flow forecast as a basic discipline. Updated weekly, the forecast gives leadership a rolling view of expected receipts, obligations, and potential cash shortfalls while there is still time to respond.
The deeper issue is whether leadership is willing to live in the future instead of constantly cleaning up the past.
The follow-on trap
The new discipline also applies to investors.
Yakatan said investors often make follow-on investments for reasons that extend beyond the company’s standalone prospects. Existing investors already have time, money, and influence tied up in the business. Additional funding may help them avoid dilution, preserve control, signal confidence to other stakeholders, or postpone writing down the investment.
That changes the investment decision. Instead of asking only whether the company deserves fresh capital, an existing investor also must consider whether withholding support would jeopardize the capital already committed.
A new investor might look at the company cold and walk away. An existing investor may keep the funding flowing because they are already “seven months pregnant,” as Yakatan put it.
That dynamic may help explain the persistence of some cannabis “zombie companies”: businesses that are not healthy enough to thrive, but not cleanly dead enough to disappear.
It also raises a harder diligence question: When an operator asks for more capital, is the money funding a business that has learned, adapted, and earned another chance? Or is it merely delaying the moment when everyone admits the original thesis is broken?
The new standard
Cannabis capital has not disappeared. It has matured.
The companies most likely to attract money now are not necessarily the loudest, biggest, or most visionary. Operators seeking capital should be ready to show not only what the money will fund, but also how the business performs today, how prior capital was deployed, when the investment will produce measurable returns, and how the company will survive if regulatory conditions do not improve.
The hype era rewarded possibility. The next era will reward operators who can prove they know how to run the business they already have.
